Jessica A Castrillon, Charis Eng, Feixiong Cheng
A standard of care therapy that acts as a brake on immune cells known as Immune checkpoint blockade (ICB) has been linked to cardiac adverse effects.
Cardio-oncology programs to reduce cardiovascular disease are limited, but pharmacogenomics may increase favorable outcomes by identifying immune-related cardiotoxicity and guiding therapy.
This article discusses the potential of recent pharmacogenomics studies in immunotherapy, highlighting several techniques that could advance the study of precision cardio-oncology.
© All Rights Reserved